
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - Psoriatic patients achieving >75 percentreduction in PASI score with one course of alefacept (Amevive) followedby treatment-free follow-up maintained >50 percent reduction for at leasteight months.